Navigation Links
Positive Results from Phase IIa Study Pave Way for Phase IIb Trial of DG051 for the Prevention of Heart Attack
Date:1/9/2008

REYKJAVIK, Iceland, Jan. 9 /PRNewswire-FirstCall/ -- deCODE genetics (Nasdaq: DCGN) today announced positive topline results from its Phase IIa clinical trial for DG051, the company's leukotriene A4 hydrolase inhibitor being developed for the prevention of heart attack. With these results, the company has finalized the design of a Phase IIb trial for which it expects to begin enrolling patients this spring. The company will discuss the development of DG051 and the rest of its product portfolio in its presentation at the JP Morgan 26th Annual Healthcare Conference. The presentation, to be delivered on Thursday January 10 at 11:30am PST/2:30pm EST/7:30pm GMT, will be webcast live via the investors' section of the company's website at http://www.decode.com.

In several studies conducted in healthy volunteers last year, DG051 was shown to reduce the production of leukotriene B4 (LTB4) in a dose-dependent manner. LTB4 is a pro-inflammatory molecule that deCODE's gene discovery and functional biology work identified as a one of the factors modulating risk of heart attack. The results of the double-blind, placebo-controlled Phase IIa study completed last month confirm that DG051 also delivers significant dose- dependent reductions in LTB4 in patients with a history of heart attack or coronary artery disease and who were taking a variety of concomitant medications. The pharmacokinetic and safety profiles of the compound were favorable and similar to those seen in previous studies in healthy volunteers. There were no serious adverse events in the study. The Phase IIb study, that will begin in the spring, will be a 400 patient, double-blind placebo- controlled study further examining its pharm
'/>"/>

SOURCE deCODE genetics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
3. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
4. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
5. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
6. NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia
7. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
8. Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
9. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
10. Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
11. European Unions CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... -- Today the US Surgeon General issued the most stern warning ... burns stating they can lead directly to deadly melanoma skin ... says that "skin cancer is a major public health problem ... indoor and outdoor ultraviolet light is a major cause." At ... Boca Raton, Florida , Marta I. Rendon ...
(Date:7/30/2014)... , July 30, 2014 Research ... "Global and Chinese Aseptic Packaging Industry Report 2014" ... http://photos.prnewswire.com/prnh/20130307/600769 The Global and Chinese ... study on the current state of the global Aseptic ... The report provides a basic overview of the ...
(Date:7/30/2014)... 30, 2014  InnoPharma, Inc. today announced the first ... equivalent of Zyprexa® injection), in Canada.  Olanzapine is indicated ... in patients with schizophrenia or bipolar I mania. ... InnoPharma has entered into an agreement with Sandoz Canada ... make, use, sell, market and distribute Olanzapine Injection in ...
Breaking Medicine Technology:Indoor and Outdoor Sun Tanning or Sun Burns Directly Linked to Deadly Melanoma Skin Cancer 2Global and Chinese Aseptic Packaging Industry Report 2014 2InnoPharma Announces Launch of Olanzapine for Injection, 10mg/vial in Canada 2
... Life Technologies Corporation (NASDAQ: ... an agreement with GlaxoSmithKline Biologicals S.A. (GSK) to develop ... with a GSK candidate cancer immunotherapy. Specifically, Life will ... cancer immunotherapy candidate designed to identify patients likely to ...
... Desert Radiologists has earned Breast MRI accreditation from ... first facility in Las Vegas to receive this prestigious ... that the breast MRI at Desert Radiologists meets ACR,s ... quality control procedures and quality assurance programs. ...
Cached Medicine Technology:Life Technologies Signs Agreement with GlaxoSmithKline Biologicals S.A., Seeking Expanded Use of Platform Technologies into Companion Diagnostics 2Life Technologies Signs Agreement with GlaxoSmithKline Biologicals S.A., Seeking Expanded Use of Platform Technologies into Companion Diagnostics 3Life Technologies Signs Agreement with GlaxoSmithKline Biologicals S.A., Seeking Expanded Use of Platform Technologies into Companion Diagnostics 4Desert Radiologists Earns ACR Breast MRI Accreditation 2
(Date:7/30/2014)... mutationslong known to fuel cancer as well as evolutionary ... rare events that occur randomly throughout the genome. , ... involves the formation of multiple mutations that arise simultaneously ... of clustered mutations are frequently found in regions where ... the journal Cell Reports , may one day ...
(Date:7/30/2014)... Hamilton Facial Plastic Surgery is ... office on July 30th. After months of planning, Dr. ... the state-of-the-art suite, located only steps away from the ... for one-on-one patient comfort, shorter wait times, and generally ... Hamilton’s new office-suite will continue to provide the same ...
(Date:7/30/2014)... NJ. July 30, 2014. A new network of 25 ... Stroke Trials Network (NIH StrokeNet) is working to ... U.S. Despite advances of the last two decades, ... stroke causes death or disability for 795,000 Americans. The ... of the population. , To accelerate the pace ...
(Date:7/30/2014)... 30, 2014 Over 630 doctors worldwide ... Technique®, the revolutionary minimally invasive treatment for gum recession. ... many of his peers to be the “father of ... a recent Chao Pinhole Surgical Technique® training course at ... is the recipient of the American Academy of Periodontics ...
(Date:7/30/2014)... Children’s Hospital of Michigan Foundation and Kohl’s invite ... to 7 p.m. Wednesday, August 6 at the Kohl’s ... 48152). The event will feature Detroit Red Wings defenseman ... and local public safety officials. Kohl’s will present a ... Foundation. , The gift supports Kohl’s Injury Prevention ...
Breaking Medicine News(10 mins):Health News:Biologists describe mechanism promoting multiple DNA mutations 2Health News:Hamilton Facial Plastic Surgery Opens New Carmel Office 2Health News:Kessler funded as satellite site for NIH Stroke Trials Network 2Health News:Periodontist Dr. Dennis Shanelec Comments On The Chao Pinhole Surgical Technique® Training Course 2Health News:Kohl’s, Children’s Hospital of Michigan Foundation Host Safety Day with Detroit Red Wings Defenseman Danny DeKeyser, Bike Helmets, Family Activities and More 2Health News:Kohl’s, Children’s Hospital of Michigan Foundation Host Safety Day with Detroit Red Wings Defenseman Danny DeKeyser, Bike Helmets, Family Activities and More 3Health News:Kohl’s, Children’s Hospital of Michigan Foundation Host Safety Day with Detroit Red Wings Defenseman Danny DeKeyser, Bike Helmets, Family Activities and More 4
... to a,recently published study, frequent mobile phone users ... study investigating the long term,effects of mobile phone ... that,frequent mobile phone users showed better focused attention, ... to making more phone calls in,distractive surroundings. No ...
... Hope, Jewelry Collection Donates 100% of Net Profits to The ... Ovarian Cancer ... commemorates,the 10th anniversary of its partnership with The Ovarian Cancer Research,Fund ... the past decade, L,Oreal Paris has offered hope to the tens ...
... 2007 -- WASHINGTON, DC) The Society for Cardiovascular ... Cardiology (ACC) announced today that they will hold a ... 2008. The meeting will be known as The SCAI ... It will be held concomitantly with the ACC Annual ...
... cases, patients never take these important medications again, study ... American seniors stop taking medications for chronic health problems ... exceed spending limits in their Medicare prescription drug plans, ... nonprofit research organization the RAND Corporation, also found that ...
... Va., Sept. 11 As part of an,initiative ... the cities visited,during its annual scientific meetings, the ... partnering with The Wellness Community -,South Bay Cities ... Volunteers from The Wellness Community will join forces ...
... , TUESDAY, Sept. 11 (HealthDay News) -- Short-term weight ... a new study shows. , Patients who gain as ... few weeks may require hospitalization within the month, according ... than 10 pounds are eight times more likely than ...
Cached Medicine News:Health News:'Slowed Brain-Activity' in Frequent Mobile Phone Users 2Health News:L'Oreal Paris Celebrates Ten Years of Hope and Healing 2Health News:L'Oreal Paris Celebrates Ten Years of Hope and Healing 3Health News:L'Oreal Paris Celebrates Ten Years of Hope and Healing 4Health News:L'Oreal Paris Celebrates Ten Years of Hope and Healing 5Health News:SCAI and ACC announce new interventional cardiology meeting 2Health News:Medicare Spending Caps Cause Seniors to Stop Meds 2Health News:ASTRO, Wellness Community South Bay Cities Join to Promote Cancer Survivorship 2Health News:Weight Gain May Spell Trouble for Heart Failure Patients 2
... providers can code the charge while completing a ... while away from office, both directly feeding the ... an Encounter Form/Superbill, data entry can be done ... patient payments are posted by reflecting open item ...
The CH 2000 Cardiac Diagnostic system is a fully featured stress testing system that can include Microvolt T-Wave Alternans (MTWA) testing capability as an add-on feature. , ,Interfaces with Tra...
The HearTwave system is the original stand-alone Microvolt T-Wave Alternans (MTWA) testing platform....
... features 4 precisely angled 64° mirrors to ... anterior chamber angle with slight rotation. ... element) provides a stable platform during laser ... mirror lens provides a complete view of ...
Medicine Products: